Plasma NGAL in APN Patients

January 25, 2025 updated by: Elsayed Abdelhalim Elsayed, Kafrelsheikh University

Plasma NGAL as a Predictor to Acute Pyelonephritis : Case -Control Cohort Study .

In recent years, novel biomarkers of renal dysfunction have attracted attention for the diagnosis of UTIs. NGAL is a 25 kDa protein that belongs to the lipocalin. It acts as a transporter for small hydrophobic molecules and is involved in many physiological processes, such as modulating inflammation, innate immune response, and maintaining metabolic homeostasis

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

120

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Zagazig, Egypt, 44749
        • Elsayed Abdelhalim Elsayed

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

All adult patient had fever due to renal infection

Description

Inclusion Criteria:

  • above 20 years Suspected have pyelonphirtis

Exclusion Criteria:

  • age below 20

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Group A :patient with pyelonephritis
patient with pyelonephritis
Human neutrophil gelatinase-associated lipocalin ELISA Kit from BT LAB® Bioassay technology laboratory was used for the estimation of serum NGAL. Procedure was done according to the manufacturer's instructions.
Group B :patient without pyelonephritis
patient without pyelonephritis
Human neutrophil gelatinase-associated lipocalin ELISA Kit from BT LAB® Bioassay technology laboratory was used for the estimation of serum NGAL. Procedure was done according to the manufacturer's instructions.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Result of plasma NGAL test
Time Frame: One day
Result of serum test of NGAL
One day

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 1, 2024

Primary Completion (Actual)

June 1, 2024

Study Completion (Actual)

June 1, 2024

Study Registration Dates

First Submitted

January 25, 2025

First Submitted That Met QC Criteria

January 25, 2025

First Posted (Actual)

March 25, 2025

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

January 25, 2025

Last Verified

January 1, 2025

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pyelonephritis

Clinical Trials on Plasma NGAL test

Subscribe